- Home
- LXRX vs MCRB Comparison
LXRX vs MCRB Comparison
Compare LXRX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- MCRB
- Stock Information
- Founded
- LXRX 1995
- MCRB 2010
- Country
- LXRX United States
- MCRB United States
- Employees
- LXRX N/A
- MCRB N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- MCRB Health Care
- Exchange
- LXRX Nasdaq
- MCRB Nasdaq
- Market Cap
- LXRX 124.4M
- MCRB 141.9M
- IPO Year
- LXRX 2000
- MCRB 2015
- Fundamental
- Price
- LXRX $0.51
- MCRB $0.37
- Analyst Decision
- LXRX Buy
- MCRB Hold
- Analyst Count
- LXRX 4
- MCRB 5
- Target Price
- LXRX $3.67
- MCRB $4.00
- AVG Volume (30 Days)
- LXRX 32.2M
- MCRB 1.3M
- Earning Date
- LXRX 05-01-2025
- MCRB 05-07-2025
- Dividend Yield
- LXRX N/A
- MCRB N/A
- EPS Growth
- LXRX N/A
- MCRB N/A
- EPS
- LXRX N/A
- MCRB 0.00
- Revenue
- LXRX $31,081,000.00
- MCRB N/A
- Revenue This Year
- LXRX N/A
- MCRB N/A
- Revenue Next Year
- LXRX $63.36
- MCRB N/A
- P/E Ratio
- LXRX N/A
- MCRB $474.36
- Revenue Growth
- LXRX 2481.48
- MCRB N/A
- 52 Week Low
- LXRX $0.28
- MCRB $0.46
- 52 Week High
- LXRX $2.45
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- LXRX 53.30
- MCRB 28.34
- Support Level
- LXRX $0.48
- MCRB $0.36
- Resistance Level
- LXRX $0.60
- MCRB $0.67
- Average True Range (ATR)
- LXRX 0.09
- MCRB 0.07
- MACD
- LXRX 0.01
- MCRB -0.02
- Stochastic Oscillator
- LXRX 42.86
- MCRB 2.71
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.